comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 22:52:10 - browse：3314

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： How the BIOSECURE Act is already affecting U.S., Chinese life science firms

hotspot

Wikipedia

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

'Essentially witchcraft:' A former naturopath takes on the field

Clinical trials giant ICON acquires HumanFirst

My daughter's legacy lives on through her writing, phage therapy

Clinical trials giant ICON acquires HumanFirst

Congress gives doctors Medicare pay bump

leisure time

comprehensive

leisure time

Peter Hotez and the public health issue of online harassment

Flu vaccine offering decent levels of protection this winter, new data show

Peter Hotez and the public health issue of online harassment

ALS groups 'won't be played again' by the FDA, drug sponsors

Continuity nursing helped my family in our darkest PICU moments

Covid isolation guidance eased by the CDC

Dobbs anniversary: the lost opportunity of abortion as health care

Teladoc has a new CEO, but challenges remain the same

Alkermes shareholders re

Curing rare childhood diseases will falter unless Congress steps up

focus

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Cheap, fast test for Zika and dengue could cost just $1

Cheap, fast test for Zika and dengue could cost just $1

Stephen Quake on the Chan Zuckerberg quest to conquer disease

RaDonda Vaught to speak at CommonSpirit event on patient safety

Change Healthcare cyberattack outage could last weeks

hotspot

focus

Wikipedia

focus